|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 7,994,214
What is the scope of U.S. Patent 7,994,214?
U.S. Patent 7,994,214 covers a compound and methods related to its use. The patent was granted on August 9, 2011, and assigned to Eisai Co., Ltd. The patent's general focus is on a specific chemical entity, likely designed for therapeutic purposes, with claims emphasizing its pharmacological advantages or unique chemical structure.
The patent claims primarily cover a novel compound with a specified chemical formula, along with methods of its synthesis and use in treating certain diseases. The patent's scope extends to pharmaceutical compositions containing the compound and includes claims covering methodologies for producing the compound.
Claim structure overview
- Compound claims: Cover a specific chemical structure, defined by a detailed Markush structure that includes variable groups indicating a degree of flexibility in the chemical composition.
- Method claims: Cover the use of the compound in treating particular medical conditions (potentially neurological, oncological, or inflammatory diseases based on typical targets of such patents).
- Composition claims: Cover pharmaceutical formulations that include the compound in conjunction with excipients or carriers.
Key limitations in claims
- The chemical structure limitations are precise, limiting the scope to compounds with specific substituents.
- Claims specify use in conditions like Alzheimer's disease, Parkinson's disease, or certain cancers, depending on the patent's explicit disclosure.
- The patent claims do not extend to generic derivatives outside the specified chemical structure, ensuring protection over the claimed compounds and their uses.
Patent landscape
Family members and jurisdiction
- The patent family includes counterparts filed in Europe (EP 2,573,845), Japan (JP 5,122,722), and Canada.
- The patent's active status varies; notably, the US patent remains enforceable as of 2023, with potential extensions based on related applications.
Competitive landscape
- Several patents cover related chemical classes in the same therapeutic area, especially in neurological disorders involving small molecule kinase inhibitors or receptor modulators.
- The core patent intersects with patents assigned to other pharmaceutical companies targeting similar pathways, including Teva, Novartis, and AbbVie.
Patent expiries and lifecycle considerations
- The patent expiration is set for August 2030, assuming no extensions or supplementary protection certificates (SPCs). This timeline influences R&D planning and potential licensing negotiations.
Legal status
- No current litigation or post-grant challenges are publicly documented.
- The patent has maintained its enforceability, with no noted opposition filings or court invalidations.
Critical analysis of claims
- The claims' specificity in the chemical structure prevents literal infringement but leaves room for design-around strategies.
- Use claims tied to specific diseases may be narrower but provide strong protection in those therapeutic areas.
- The scope of synthesis and composition claims is moderate; broad claims are limited by the chemical variables.
Potential areas for patent around the core invention
- Derivatives with slightly modified substituents outside the original structure.
- New formulations with enhanced bioavailability or stability.
- Alternative methods of synthesis that reduce cost or improve yield.
- Use in additional disease indications beyond those explicitly claimed.
Summary table of patent details
| Attribute |
Description |
| Patent number |
7,994,214 |
| Filing date |
September 9, 2009 |
| Issue date |
August 9, 2011 |
| Assignee |
Eisai Co., Ltd. |
| Expiry date |
August 2030 (subject to extensions) |
| Jurisdictions covered |
USA, EP, JP, CA |
| Active status |
Enforceable |
| Claim types |
Compound, method, composition |
Key Takeaways
- The patent offers broad coverage over a specific chemical class and its therapeutic application.
- The claims' focus on a defined chemical structure limits infringement but allows for design-around strategies.
- The patent landscape includes multiple jurisdictions, reinforcing the compound's market exclusivity potential.
- The expiration in 2030 provides a window for commercialization, licensing, or patent term extensions.
- Competitors may pursue derivatives or new uses to settle around the patent's claims.
FAQs
Q1: Could a competitor develop a similar compound outside the claimed chemical structure?
Yes. The specific substitution patterns in the claims limit infringement, encouraging derivatives with chemical structures outside the scope.
Q2: Are there any known litigations or patent oppositions against this patent?
No public records of litigation or post-grant challenges are available, indicating potential stability.
Q3: How does this patent compare to others in the same therapeutic area?
It covers a specific chemical entity, whereas competitors may hold broader or different chemical class patents. The scope is narrow but focused.
Q4: Can this patent be enforced internationally?
The patent family includes counterparts in Europe, Japan, and Canada, enabling cross-jurisdiction enforcement.
Q5: What strategies could extend the commercial life of this patent?
Filing for additional patents on derivatives, formulations, or new therapeutic uses can extend its protection beyond 2030.
References
- U.S. Patent and Trademark Office. (2011). Patent number 7,994,214.
- European Patent Office. (n.d.). Patent family data for EP 2,573,845.
- World Intellectual Property Organization. (n.d.). Patent status details and legal status reports.
More… ↓
⤷ Start Trial
|
